Austin, Texas (PRWEB) July 25, 2013
Pure Transplant Solutions, LLC (PTS) a biotechnology start-up company looking to revolutionize the future of transplantation medicine, has launched a campaign on the crowdfunding site, Indiegogo.com, to raise awareness and development funds of $100,000 in 45 days for its proprietary, selective Antibody Removal Column (the ARCTM). The ARC is a medical device that filters and selectively removes harmful antibodies from an organ recipient’s blood to allow an organ of a non-matched donor to be transplanted into the recipient, without the usual risk of organ rejection. The name of the PTS Indiegogo campaign is "Any Organ Any Body".
According to the Organ Procurement and Transplantation Network (OPTN), it is estimated that over 215,000 Americans die yearly from diseases that are treatable by transplant. Each day, an average of 79 people receive a transplant, but on that same day, an average of 18 people die waiting for one. The length of time a person has to wait for a transplant depends on many things but is primarily determined by the degree of matching between a person and a donor.
More than 80% of US transplant candidates are waiting for kidneys. One third of patients waiting for a kidney are considered to be “highly sensitized” meaning they have high levels of harmful antibodies and may never be matched with a donor no matter how long they are on the waiting list.
The ARC directly addresses this issue by allowing living donors to donate a kidney. “This technology would make it possible for the people who care most, to donate their organ to those they love most, but with whom they do not match for tissue type; with less reliance on the organ banks,” said Dr. Gina Lento, PTS Vice President. “The ARC not only decreases the risk of organ rejection, but is also much saf
Copyright©2012 Vocus, Inc.
All rights reserved